Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
9.10
Dollar change
-0.36
Percentage change
-3.81
%
Index- P/E- EPS (ttm)-1.16 Insider Own47.11% Shs Outstand30.74M Perf Week-2.78%
Market Cap295.11M Forward P/E- EPS next Y-0.97 Insider Trans-1.61% Shs Float17.15M Perf Month4.60%
Income-36.24M PEG- EPS next Q-0.27 Inst Own28.73% Short Float0.68% Perf Quarter43.76%
Sales0.31M P/S951.98 EPS this Y13.06% Inst Trans0.26% Short Ratio0.48 Perf Half Y386.63%
Book/sh2.21 P/B4.11 EPS next Y3.55% ROA-34.23% Short Interest0.12M Perf Year135.75%
Cash/sh1.51 P/C6.01 EPS next 5Y- ROE-42.86% 52W Range1.52 - 10.44 Perf YTD52.17%
Dividend Est.- P/FCF- EPS past 5Y-21.21% ROI-51.05% 52W High-12.84% Beta1.51
Dividend TTM- Quick Ratio2.51 Sales past 5Y109.61% Gross Margin-379.08% 52W Low498.68% ATR (14)0.74
Dividend Ex-Date- Current Ratio2.51 EPS Y/Y TTM18.61% Oper. Margin-12980.72% RSI (14)51.29 Volatility9.88% 8.31%
Employees57 Debt/Eq0.03 Sales Y/Y TTM14.18% Profit Margin-11843.79% Recom1.67 Target Price2.75
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q19.70% Payout- Rel Volume3.99 Prev Close9.46
Sales Surprise-56.24% EPS Surprise3.10% Sales Q/Q-36.92% EarningsMar 20 AMC Avg Volume239.50K Price9.10
SMA20-1.49% SMA509.22% SMA200112.32% Trades Volume954,568 Change-3.81%
Date Action Analyst Rating Change Price Target Change
Mar-30-22Downgrade Citigroup Buy → Neutral $18 → $4
Nov-19-21Initiated Oppenheimer Outperform $19
Oct-15-21Resumed Cowen Outperform
Today 01:32AM
Mar-27-24 01:27AM
Mar-25-24 12:00PM
Mar-21-24 09:57AM
Mar-20-24 08:54PM
05:33PM Loading…
05:33PM
05:20PM
04:05PM
Mar-12-24 11:40AM
Mar-04-24 08:30AM
Feb-29-24 11:14AM
Dec-11-23 12:00PM
Dec-06-23 01:19PM
08:30AM
Nov-22-23 01:00PM
10:59AM Loading…
Nov-12-23 10:59AM
Nov-08-23 06:29PM
04:05PM
Oct-25-23 08:30AM
Sep-21-23 08:30AM
Aug-31-23 09:35AM
Aug-30-23 09:35AM
Aug-09-23 05:50PM
04:05PM
Jul-31-23 08:30AM
May-25-23 04:15PM
May-15-23 05:15PM
May-10-23 06:05PM
04:05PM
May-04-23 07:31AM
08:30AM Loading…
Apr-27-23 08:30AM
Apr-24-23 09:35AM
Mar-27-23 12:00PM
02:27AM
Mar-24-23 06:29AM
Mar-22-23 05:35PM
04:05PM
Mar-09-23 04:05PM
Feb-23-23 04:20PM
Feb-18-23 07:43AM
Feb-15-23 08:30AM
Nov-29-22 08:30AM
Nov-15-22 08:30AM
Nov-09-22 06:15PM
04:05PM
Nov-04-22 04:00PM
Oct-04-22 08:30AM
Sep-22-22 08:30AM
Sep-20-22 07:19AM
Aug-11-22 07:00AM
Aug-10-22 05:55PM
04:05PM
Aug-03-22 10:00AM
Jul-28-22 08:30AM
Jun-06-22 02:15PM
May-19-22 04:15PM
May-18-22 03:03PM
May-10-22 04:05PM
May-05-22 08:30AM
May-02-22 08:30AM
Apr-12-22 08:30AM
Mar-30-22 07:30AM
Mar-29-22 04:00PM
Mar-18-22 12:00PM
07:00AM
Mar-03-22 08:30AM
Feb-17-22 08:30AM
Feb-07-22 08:30AM
Feb-01-22 08:30AM
Dec-15-21 08:30AM
Dec-02-21 08:00AM
Dec-01-21 11:40AM
Nov-30-21 08:00AM
Nov-10-21 09:01AM
Nov-09-21 04:01PM
Nov-08-21 04:20PM
Nov-04-21 08:00AM
Nov-03-21 08:00AM
Nov-02-21 08:00AM
Oct-27-21 08:30AM
Oct-15-21 10:59AM
Sep-28-21 08:30AM
Sep-20-21 08:30AM
Sep-15-21 08:00AM
Sep-14-21 08:00AM
Sep-13-21 08:00AM
Aug-30-21 04:05PM
Aug-17-21 08:00AM
Jul-14-21 09:03PM
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. It focuses on developing blood tests to predict the risks of preterm birth, preeclampsia and other pregnancy complications. The company was founded by Steven W. Graves, Dennis Farrar and M. Sean Esplin in 2008 and is headquartered in Salt Lake City, UT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Boniface John J.Chief Scientific OfficerMar 28 '24Option Exercise0.9124,47422,271164,245Mar 28 05:56 PM
Boniface John J.Chief Scientific OfficerMar 28 '24Sale9.0424,474221,245139,771Mar 28 05:56 PM
Boniface John J.Chief Scientific OfficerMar 27 '24Option Exercise0.9148,90944,507188,680Mar 28 05:56 PM
Boniface John J.Chief Scientific OfficerMar 27 '24Sale9.6252,662506,608139,771Mar 28 05:56 PM
Lindgardt ZhenyaChief Executive OfficerMar 26 '24Sale9.3738,899364,484908,104Mar 26 08:00 PM
Boniface John J.Chief Scientific OfficerMar 26 '24Sale9.5521,438204,733143,524Mar 26 05:38 PM
Aerts AustinChief Financial OfficerMar 26 '24Sale9.378,09275,822322,488Mar 26 08:00 PM
Boniface John J.Chief Scientific OfficerMar 25 '24Sale9.1022,163201,683164,962Mar 26 04:20 PM
Harrison Robert GardnerChief Information OfficerMar 06 '24Sale9.022,13819,285145,697Mar 07 04:15 PM
Jackson BenjaminGeneral CounselMar 06 '24Sale9.021,85616,741150,179Mar 07 04:15 PM
Boniface John J.Chief Scientific OfficerMar 06 '24Sale9.021,66415,009187,125Mar 07 04:16 PM
Kearney PaulChief Data OfficerMar 06 '24Sale9.021,0289,273159,038Mar 07 04:16 PM
Aerts AustinChief Financial OfficerMar 06 '24Sale9.024444,005330,580Mar 07 04:16 PM
Lindgardt ZhenyaChief Executive OfficerFeb 06 '24Sale8.0327,997224,816947,003Feb 07 04:56 PM
Aerts AustinChief Financial OfficerFeb 06 '24Sale8.039,78678,582331,024Feb 07 04:56 PM
Boniface John J.Chief Scientific OfficerFeb 06 '24Sale8.035,66545,490188,789Feb 07 04:57 PM
Jackson BenjaminGeneral CounselFeb 06 '24Sale8.035,66545,490152,035Feb 07 04:57 PM
Harrison Robert GardnerChief Information OfficerFeb 06 '24Sale8.035,66545,490147,835Feb 07 04:56 PM
Kearney PaulChief Data OfficerFeb 06 '24Sale8.034,98440,022160,066Feb 07 04:56 PM
Jackson BenjaminGeneral CounselDec 07 '23Sale5.2210,00052,200157,700Dec 07 09:35 PM
Boniface John J.Chief Scientific OfficerDec 07 '23Sale4.805,00024,000194,454Dec 07 09:35 PM
Harrison Robert GardnerChief Information OfficerJun 05 '23Sale3.235,00016,15028,500Jun 06 04:07 PM
Kearney PaulChief Data OfficerApr 06 '23Option Exercise0.7524,05018,03840,050Apr 07 04:14 PM